What is the 13F Pro Quality Score for PETS?

13F Pro ranks PETMED EXPRESS INC (PETS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PETS's current score at https://13fpro.ai/research/PETS (free sign-up required for the full ranking).

Where does 13F Pro source PETS data?

All PETMED EXPRESS INC fundamentals and ownership data come directly from SEC EDGAR. PETMED EXPRESS INC files with the SEC under CIK 1040130. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PETS in?

PETMED EXPRESS INC (PETS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is PETS research updated on 13F Pro?

PETS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

PETMED EXPRESS INC(PETS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1040130 PETS stock profile & AI dashboard →

13F Pro Quality Score

15.3/100

Rank #2,750 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

6.0/100

Profitability

13.0/100

Balance Sheet

1.9/100

Earnings Quality

30.0/100

Free Cash Flow

15.5/100

Institutional Flow

12.4/100

Revenue Scale

23.6/100

Dilution Risk

64.6/100

PETS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for PETMED EXPRESS INC (PETS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PETS at 15.3/100 on a 32-signal composite quality model, placing it at rank #2,750 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (1.9) and revenue growth (6.0), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q4 2026), PETMED EXPRESS INC reports quarterly revenue of $42.8M, net income of $-4.1M, free cash flow of $-5.5M. Top institutional holders of PETS by reported 13-F value include RENAISSANCE TECHNOLOGIES, VANGUARD CAPITAL MANAGEMENT, FEDERATED HERMES,, based on the most recent SEC filings. PETS trades on the Nasdaq exchange and files with the SEC under CIK 1040130. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PETS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PETMED EXPRESS INC directly from SEC EDGAR. PETMED EXPRESS INC's 13F Pro composite quality score has ranged between 15 and 34 since 2024, currently 15.3 — a declining long-term trajectory across 17 quarterly and live scoring snapshots.

✦

Fun facts about PETMED EXPRESS INC

Quirks, history, and lore behind PETS — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. direct-to-consumer company · listed on Nasdaq · headquartered in Florida · operates in a specialized retail niche.
2
The Numbers
Annual revenue in the range of $300 million — not a giant, but a consistent player in a market where Americans spend over $30 billion a year and climbing.
3
The History
Founded in the late 1990s, it was an early bet that consumers would happily skip the middleman and order a recurring necessity online and by phone rather than drive to a storefront.
4
The Secret
Its business is essentially a mail-order pharmacy — but the customers it's filling prescriptions for can't read the label themselves and are very good boys and girls.
5
The Lore
It competes fiercely with big-box retailers and vet clinics for a slice of every flea-and-tick treatment, heartworm pill, and arthritis medication dispensed to America's beloved four-legged dependents.
6
The Giveaway
The name literally says it all: medication delivered to your door for your dog or cat — and its ticker symbol is the most on-the-nose three letters on Wall Street.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q4 2026

$42.8M

Net Income

Q4 2026

$-4.1M

Free Cash Flow

Q4 2026

$-5.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-34.7% YoY

$179.0MFY 2026

FY20 $284.1MFY22 $272.3MFY24 $274.1MFY26 $179.0M

Net Income

-667.9% YoY

$-57.3MFY 2026

FY20 $25.9MFY22 $18.7MFY24 $-7.5MFY26 $-57.3M

Operating Income

-618.9% YoY

$-58.7MFY 2026

FY20 $31.0MFY22 $24.3MFY24 $-8.2MFY26 $-58.7M

EPS (Diluted)

-640.5% YoY

$-2.74FY 2026

FY20 $1.29FY22 $0.92FY24 $-0.37FY26 $-2.74

Total Assets

-52.2% YoY

$81.2MFY 2026

FY20 $155.3MFY22 $176.3MFY24 $169.9MFY26 $81.2M

Op. Cash Flow

-757.7% YoY

$-28.4MFY 2026

FY20 $38.8MFY22 $18.5MFY24 $4.3MFY26 $-28.4M

Metric	FY 2026	FY 2024	FY 2022	FY 2020	FY 2019	FY 2018
Revenue	$179.0M -34.7%	$274.1M +0.7%	$272.3M -4.2%	$284.1M +0.2%	$283.4M +3.5%	$273.8M
Net Income	$-57.3M -667.9%	$-7.5M -139.9%	$18.7M -27.6%	$25.9M -31.5%	$37.7M +1.2%	$37.3M
Operating Income	$-58.7M -618.9%	$-8.2M -133.6%	$24.3M -21.6%	$31.0M -32.9%	$46.2M -11.4%	$52.1M
EPS (Diluted)	$-2.74 -640.5%	$-0.37 -140.2%	$0.92 -28.7%	$1.29 +71566.7%	$0.00 +0.0%	$0.00
Total Assets	$81.2M -52.2%	$169.9M -3.6%	$176.3M +13.5%	$155.3M +0.6%	$154.4M +14.5%	$134.8M
Operating Cash Flow	$-28.4M -757.7%	$4.3M -76.7%	$18.5M -52.4%	$38.8M -13.9%	$45.1M +20.8%	$37.4M

AI Insight: PETS Financial Trends

PETS has deteriorated sharply: revenue collapsed 35% from Q2 2024 to Q1 2026, with operating losses now structural and equity eroded 69%.

• Revenue fell from $66M (Q2 2024) to $43M (Q1 2026), a 35% decline over eight quarters with no recovery sign.

• Operating income swung from $4M profit (Q2 2024) to $6M loss (Q1 2026); company has posted losses in five of last eight quarters.

• Equity halved from $94M (Q2 2024) to $29M (Q1 2026), driven by cumulative net losses totaling ~$84M over eight quarters.

⚠ Operating cash flow turned negative in Q2 2025 (–$12M) and has remained underwater for three consecutive quarters; liquidity stress evident.

⚠ Q2 2025 marked a cliff: net loss spiked to –$34M in a single quarter; stabilization to –$4M in Q1 2026 suggests cost cuts but underlying demand erosion unresolved.

AI Insight: PETS Ratio Trends

PETS collapsed into sustained unprofitability across all return metrics; operating margin deteriorated from +6.6% in Q2 2024 to -13.3% in Q1 2026.

• Operating margin swung from +6.6% in Q2 2024 to -32.8% TTM, with nine consecutive quarters in negative territory since Q4 2024.

• ROE and ROA both deeply negative in latest quarter (–56.1% and –20.0% respectively), indicating severe capital destruction.

• ROIC sank to –78.7% in Q1 2026, the worst return on invested capital in the dataset, reflecting operational failure.

⚠ No recovery visible despite nine-quarter trend; Q1 2026 margins improved only modestly from Q4 2025 (–25.8% to –13.3%), yet remain deeply negative.

⚠ Debt/equity ratio absent from all periods, obscuring financial leverage risk during sustained losses and potential covenant stress.

Get alerted when PETS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for PETMED EXPRESS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PETS

RENAISSANCE TECHNOLOGIES LLC
$2.7M1,186,369 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.9M831,431 sh
FEDERATED HERMES, INC.
$1.5M666,805 sh
BlackRock, Inc.
$1.3M551,677 sh
HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC
$1.2M514,543 sh
UBS Group AG
$532.8K233,676 sh
GEODE CAPITAL MANAGEMENT, LLC
$505.2K221,522 sh
DIMENSIONAL FUND ADVISORS LP
$473.7K207,769 sh
STEEL PARTNERS HOLDINGS L.P.
$441.6K193,664 sh
Formidable Asset Management, LLC
$336.6K105,201 sh

Fund	Value	Shares
RENAISSANCE TECHNOLOGIES LLC	$2.7M	1,186,369
VANGUARD CAPITAL MANAGEMENT LLC	$1.9M	831,431
FEDERATED HERMES, INC.	$1.5M	666,805
BlackRock, Inc.	$1.3M	551,677
HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC	$1.2M	514,543
UBS Group AG	$532.8K	233,676
GEODE CAPITAL MANAGEMENT, LLC	$505.2K	221,522
DIMENSIONAL FUND ADVISORS LP	$473.7K	207,769
STEEL PARTNERS HOLDINGS L.P.	$441.6K	193,664
Formidable Asset Management, LLC	$336.6K	105,201

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PETS on your watchlist

Track score changes the day PETMED EXPRESS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PETS a good stock to buy?

13F Pro's AI-powered analysis of PETMED EXPRESS INC (PETS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PETS are available on the PETS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PETS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PETS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PETMED EXPRESS INC's investment landscape.